Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Hubei Biocause Pharmaceutical Co Ltd
Net Issuance of Debt
Hubei Biocause Pharmaceutical Co Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
|
Net Issuance of Debt
-¥8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
China Life Insurance Co Ltd
SSE:601628
|
Net Issuance of Debt
-¥33.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ping An Insurance Group Co of China Ltd
SSE:601318
|
Net Issuance of Debt
-¥45.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
New China Life Insurance Company Ltd
SSE:601336
|
Net Issuance of Debt
¥138.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
151%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sunshine Insurance Group Co Ltd
HKEX:6963
|
Net Issuance of Debt
¥21.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hubei Biocause Pharmaceutical Co Ltd
Glance View
Hubei Biocause Pharmaceutical Co., Ltd began its journey in the health sector by positioning itself strategically in the pharmaceutical industry. With its headquarters set in the Hubei Province of China, this company has intricately woven itself into the fabric of modern healthcare. Primarily, it thrives by developing, manufacturing, and distributing a variety of pharmaceutical products including both traditional and modern-medicine drugs. The journey of Biocause is punctuated by its research-driven approach, which focuses on innovation and quality control across its production lines, ensuring it stays at the forefront of pharmaceutical advancements. Revenue generation for Hubei Biocause predominantly comes from the sale of medications and healthcare products, but the company's financial tapestry is more diversified. It has explored opportunities by extending its business horizon beyond pharmaceuticals, tapping into other ventures such as insurance services. This diversification has enabled Biocause to stabilize its financial structure and mitigate risk, leveraging its steady pharma income to branch into realms that complement its healthcare base. Alongside, their strategic partnerships and alliances further bolster their market position, allowing for a broadened geographical reach and a more substantial impact on the sectors they operate within. Thus, Hubei Biocause crafts a story not only of pharmaceutical excellence but of strategic breadth that spawns wider market opportunities.
See Also
What is Hubei Biocause Pharmaceutical Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
-8B
CNY
Based on the financial report for Sep 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Net Issuance of Debt amounts to -8B CNY.
What is Hubei Biocause Pharmaceutical Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
-42%
Over the last year, the Net Issuance of Debt growth was -258%.
You don't have any saved screeners yet